COMMUNIQUÉS West-GlobeNewswire
-
Alira Health Opens the Registration for the Third Edition of the Global Payer Forum
29/01/2026 -
Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy
29/01/2026 -
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
29/01/2026 -
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
29/01/2026 -
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
29/01/2026 -
NetraMark Strengthens Board Of Directors
29/01/2026 -
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
29/01/2026 -
Terrapin Beer Co. Turns Up the Volume with a New Brand Identity Rooted in Music, Art and Craft Beer Culture
29/01/2026 -
Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development
29/01/2026 -
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
29/01/2026 -
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
29/01/2026 -
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
29/01/2026 -
INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
29/01/2026 -
Glass House Brands Announces Appointment of Alison Payne, Heineken USA Chief Marketing Officer, to its Board of Directors
29/01/2026 -
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
29/01/2026 -
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
29/01/2026 -
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
29/01/2026 -
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
29/01/2026 -
InnovAge Expands Board with Appointment of Two Directors
29/01/2026
Pages